Holly Robinson Peete Partners with Supernus to Raise Awareness During ADHD Awareness Month

• Peete and her daughter Ryan join forces to amplify the conversation around Attention-deficit/Hyperactivity disorder (ADHD) and neurodiversity
• Nearly one-in-ten – or 6.1 million children and adolescents – are affected by ADHD
  

ROCKVILLE, Md., Oct. 20, 2021 (GLOBE NEWSWIRE) -- Actress, host, influencer, and mother, Holly Robinson Peete is partnering with Supernus Pharmaceuticals to raise awareness of Attention-deficit/Hyperactivity disorder (ADHD) – a neurodevelopmental condition that is one of the most common and treatable mental conditions affecting children and adolescents in the U.S., including her daughter Ryan.

Peete, who has been open about her own family’s challenges raising neurodiverse children, is speaking up this October during ADHD Awareness Month to shatter stigmas and encourage those who think their child may have ADHD to learn more and seek treatment.

“Before my daughter Ryan was diagnosed with ADHD, I didn’t know much about the condition – I thought it meant you couldn’t keep still, you were fidgety, or were just considered unteachable; but this is not the case,” Holly Robinson Peete says. “Just like children with ADHD many of us have unique personality traits. We need to recognize that we live in a neurodiverse world, and I want those living with ADHD to know they are not alone, they are more than their diagnosis and there is help to overcome their specific challenges.”

Throughout ADHD Awareness Month and beyond, adults and adolescents alike are encouraged to join the conversation sharing their experiences living with the condition. More To ADHD offers downloadable resources to support those struggling including information on the signs and symptoms, which are not always easy to spot and treatments. Additionally, the website provides tips and checklists to guide discussions with your child’s teacher and healthcare provider.

"We know that a diagnosis of ADHD is scary and can make families feel alone and helpless,” Jack A. Khattar, President and Chief Executive Officer of Supernus Pharmaceuticals says. “We’re thrilled to have Holly Robinson Peete and her daughter Ryan open up about their journeys with ADHD, and now using her platform to change the conversation surrounding ADHD and give voice to a neurodiverse community that has for so long been overlooked.”

For more information, visit MoreToADHD.com to sign up to learn more, find resources to help with recognizing, treating, and managing ADHD.

About Supernus Pharmaceuticals, Inc.

Supernus Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. Our diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson’s disease, cervical dystonia and chronic sialorrhea. We are developing a broad range of novel CNS product candidates including new potential treatments for hypomobility in Parkinson’s disease, epilepsy, depression, and rare CNS disorders.

For more information, please visit www.supernus.com

Forward-Looking Statements:

This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements do not convey historical information, but relate to predicted or potential future events that are based upon management's current expectations. These statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. In addition to the factors mentioned in this press release, such risks and uncertainties include, but are not limited to, the Company’s ability to sustain and increase its profitability; the Company’s ability to raise sufficient capital to fully implement its corporate strategy; the implementation of the Company’s corporate strategy; the Company’s future financial performance and projected expenditures; the Company’s ability to increase the number of prescriptions written for each of its products; the Company’s ability to increase its net revenue; the Company’s ability to enter into future collaborations with pharmaceutical companies and academic institutions or to obtain funding from government agencies; the Company’s product research and development activities, including the timing and progress of the Company’s clinical trials, and projected expenditures; the Company’s ability to receive, and the timing of any receipt of, regulatory approvals to develop and commercialize the Company’s product candidates; the Company’s ability to protect its intellectual property and operate its business without infringing upon the intellectual property rights of others; the Company’s expectations regarding federal, state and foreign regulatory requirements; the therapeutic benefits, effectiveness and safety of the Company’s product candidates; the accuracy of the Company’s estimates of the size and characteristics of the markets that may be addressed by its product candidates; the Company’s ability to increase its manufacturing capabilities for its products and product candidates; the Company’s projected markets and growth in markets; the Company’s product formulations and patient needs and potential funding sources; the Company’s staffing needs; and other risk factors set forth from time to time in the Company’s filings with the Securities and Exchange Commission made pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended. The Company undertakes no obligation to update the information in this press release to reflect events or circumstances after the date hereof or to reflect the occurrence of anticipated or unanticipated events.

CONTACT:
Jack A. Khattar, President and CEO
Timothy Dec, Senior Vice President and CFO
Supernus Pharmaceuticals, Inc.
Tel: (301) 838-2591

Or

Media Contact:
Alice Sofield
Mobile: (703) 861-5654
Email: [email protected]

Investor Contact:
Peter Vozzo
Westwicke, an ICR Company
Office: (443) 213-0505
Mobile: (443) 377-4767
Email: [email protected]